SWOG 0711: Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517, IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction
December 08, 2009
Cancer - Breast/ Gastro/ Lung/ Lymphoma/ Thyroid
Principal Investigator: Robert A Chapman, MD
The purpose of this study is to find out how Dasatinib behaves in advanced cancer in patients with abnormal liver function. Dasatinib acts to slow down or prevent growth signals or messages in cancer cells.
Patients must have histologically or cytologically confirmed solid tumor or lymphoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; Patients must have measurable or non-measurable disease. X-rays and/or scans for disease assessment must have been completed within 28 days (for measurable disease) or 42 days (for non-measurable disease) prior to registration; Patients must be 18 years of age or older.